TD Cowen Maintains Outperform on Milestone Pharmaceuticals, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
TD Cowen has maintained an Outperform rating on Milestone Pharmaceuticals (NASDAQ:MIST) but has reduced the price target from $17 to $9. This adjustment reflects a change in valuation expectations for MIST, although the Outperform rating indicates continued confidence in the company's performance.

December 27, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TD Cowen maintains an Outperform rating on Milestone Pharmaceuticals but cuts the price target from $17 to $9, signaling a reassessment of the company's valuation while still expressing optimism.
The reduction in price target by TD Cowen could have a mixed impact on MIST's stock price in the short term. On one hand, the lowered price target may suggest to investors that the stock's future growth potential is not as high as previously thought, which could lead to a negative reaction in the stock price. On the other hand, maintaining an Outperform rating indicates that TD Cowen still has confidence in the company's ability to perform well, which could help mitigate any negative impact from the price target reduction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100